Deferasirox Mylan

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

deferasirox

Available from:

Mylan Pharmaceuticals Limited

ATC code:

V03AC03

INN (International Name):

deferasirox

Therapeutic group:

Željeza chelation

Therapeutic area:

Iron Overload; beta-Thalassemia

Therapeutic indications:

Деферазирокс Mylan u naznačeno za liječenje kronične preopterećenje željezom zbog čestih переливаний krvi (≥7 ml/kg/mjesec эритроцитарной mase) u bolesnika s beta-талассемией gradonačelnik u dobi od 6 godina i olderthe liječenje kronične preko-zasićenih željezom zbog трансфузий krvi, kada je terapija дефероксамином kontraindiciran ili неадекватна od sljedećih skupina bolesnika:kod pedijatrijska bolesnika s beta-талассемией s preopterećenje željezom zbog čestih переливаний krvi (≥7 ml/kg/mjesec эритроцитарной mase) u dobi od 2 do 5 godina,u pedijatrijskoj i odraslih pacijenata s beta-талассемией s preopterećenje željezom zbog rijedak transfuziju krvi (.

Product summary:

Revision: 9

Authorization status:

odobren

Authorization date:

2019-09-26

Patient Information leaflet

                                48
B. UPUTA O LIJEKU
49
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
DEFERASIROKS MYLAN 90 MG FILMOM OBLOŽENE TABLETE
DEFERASIROKS MYLAN 180 MG FILMOM OBLOŽENE TABLETE
DEFERASIROKS MYLAN 360 MG FILMOM OBLOŽENE TABLETE
deferasiroks
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
–
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
–
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
–
Ovaj je lijek propisan samo Vama ili Vašem djetetu. Nemojte ga davati
drugima. Može im
naškoditi, čak i ako su njihovi znakovi bolesti jednaki Vašima.
–
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Deferasiroks Mylan i za što se koristi
2.
Što morate znati prije nego počnete uzimati Deferasiroks Mylan
3.
Kako uzimati Deferasiroks Mylan
4.
Moguće nuspojave
5.
Kako čuvati Deferasiroks Mylan
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE DEFERASIROKS MYLAN I ZA ŠTO SE KORISTI
ŠTO JE DEFERASIROKS MYLAN
Deferasiroks Mylan sadrži djelatnu tvar koja se zove deferasiroks. To
je kelator željeza, lijek koji se
koristi za uklanjanje viška željeza iz tijela (također se zove
preopterećenje željezom). On hvata i
uklanja višak željeza koje se potom izlučuje uglavnom stolicom.
ZA ŠTO SE KORISTI DEFERASIROKS MYLAN
U bolesnika s različitim vrstama anemije (npr. talasemijom, bolešću
srpastih stanica ili
mijelodisplastičnim sindromima (MDS)) može biti nužno provoditi
ponovljene transfuzije krvi. No
ponovljene transfuzije krvi mogu uzrokovati prekomjerno nakupljanje
željeza. To se događa zato što
krv sadrži željezo, a ne postoji prirodan način na koji bi tijelo
uklonilo višak željeza primljen
transfuzijama krvi. U bolesnika sa sindromima talasemije neovisnim o
transfuziji s vremenom se može
razviti i preopterećenost željezom, uglavnom zbog po
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Deferasiroks Mylan 90 mg filmom obložene tablete
Deferasiroks Mylan 180 mg filmom obložene tablete
Deferasiroks Mylan 360 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Deferasiroks Mylan 90 mg f
ilmom obložene tablete
Jedna filmom obložena tableta sadrži 90 mg deferasiroksa.
Deferasiroks Mylan 180 mg fi
lmom obložene tablete
Jedna filmom obložena tableta sadrži 180 mg deferasiroksa.
Deferasiroks Mylan 360 mg fi
lmom obložene tablete
Jedna filmom obložena tableta sadrži 360 mg deferasiroksa.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta (tableta)
Deferasiroks Mylan 90 mg f
ilmom obložene tablete
Bikonveksna filmom obložena tableta modificiranog oblika kapsule,
plave boje, s utisnutom oznakom
„
” na jednoj strani tablete i „DF” na drugoj strani.
Približne dimenzije tablete 10,00 mm × 4,5 mm.
Deferasiroks Mylan 180 mg fi
lmom obložene tablete
Bikonveksna filmom obložena tableta modificiranog oblika kapsule,
plave boje, s utisnutom oznakom
„
” na jednoj strani tablete i „DF 1” na drugoj strani.
Približne dimenzije tablete 12,8 mm × 6,00 mm.
Deferasiroks Mylan 360 mg f
ilmom obložene tablete
Bikonveksna filmom obložena tableta modificiranog oblika kapsule,
plave boje, s utisnutom oznakom
„
” na jednoj strani tablete i „DF 2” na drugoj strani.
Približne dimenzije tablete 17 mm × 6,7 mm.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Deferasiroks Mylan je indiciran za liječenje kroničnog
preopterećenja željezom zbog čestih transfuzija
krvi (≥ 7 ml/kg/mjesec koncentrata eritrocita) u bolesnika s
beta-talasemijom major u dobi od 6 godina
i starijih.
3
Deferasiroks Mylan je također indiciran za liječenje kroničnog
preopterećenja željezom zbog
transfuzija krvi kada je terapija deferoksaminom kontraindicirana ili
neodgovarajuća u sljedećim
skupinama bolesnika:
–
pedijatrijski bolesnici s beta-talasemijom major i preopterećenjem

                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 28-03-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 28-03-2023
Public Assessment Report Public Assessment Report Bulgarian 10-10-2019
Patient Information leaflet Patient Information leaflet Spanish 28-03-2023
Public Assessment Report Public Assessment Report Spanish 10-10-2019
Patient Information leaflet Patient Information leaflet Czech 28-03-2023
Public Assessment Report Public Assessment Report Czech 10-10-2019
Patient Information leaflet Patient Information leaflet Danish 28-03-2023
Public Assessment Report Public Assessment Report Danish 10-10-2019
Patient Information leaflet Patient Information leaflet German 28-03-2023
Public Assessment Report Public Assessment Report German 10-10-2019
Patient Information leaflet Patient Information leaflet Estonian 28-03-2023
Public Assessment Report Public Assessment Report Estonian 10-10-2019
Patient Information leaflet Patient Information leaflet Greek 28-03-2023
Public Assessment Report Public Assessment Report Greek 10-10-2019
Patient Information leaflet Patient Information leaflet English 28-03-2023
Public Assessment Report Public Assessment Report English 10-10-2019
Patient Information leaflet Patient Information leaflet French 28-03-2023
Public Assessment Report Public Assessment Report French 10-10-2019
Patient Information leaflet Patient Information leaflet Italian 28-03-2023
Public Assessment Report Public Assessment Report Italian 10-10-2019
Patient Information leaflet Patient Information leaflet Latvian 28-03-2023
Public Assessment Report Public Assessment Report Latvian 10-10-2019
Patient Information leaflet Patient Information leaflet Lithuanian 28-03-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 28-03-2023
Public Assessment Report Public Assessment Report Lithuanian 10-10-2019
Patient Information leaflet Patient Information leaflet Hungarian 28-03-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 28-03-2023
Public Assessment Report Public Assessment Report Hungarian 10-10-2019
Patient Information leaflet Patient Information leaflet Maltese 28-03-2023
Public Assessment Report Public Assessment Report Maltese 10-10-2019
Patient Information leaflet Patient Information leaflet Dutch 28-03-2023
Public Assessment Report Public Assessment Report Dutch 10-10-2019
Patient Information leaflet Patient Information leaflet Polish 28-03-2023
Public Assessment Report Public Assessment Report Polish 10-10-2019
Patient Information leaflet Patient Information leaflet Portuguese 28-03-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 28-03-2023
Public Assessment Report Public Assessment Report Portuguese 10-10-2019
Patient Information leaflet Patient Information leaflet Romanian 28-03-2023
Public Assessment Report Public Assessment Report Romanian 10-10-2019
Patient Information leaflet Patient Information leaflet Slovak 28-03-2023
Public Assessment Report Public Assessment Report Slovak 10-10-2019
Patient Information leaflet Patient Information leaflet Slovenian 28-03-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 28-03-2023
Public Assessment Report Public Assessment Report Slovenian 10-10-2019
Patient Information leaflet Patient Information leaflet Finnish 28-03-2023
Public Assessment Report Public Assessment Report Finnish 10-10-2019
Patient Information leaflet Patient Information leaflet Swedish 28-03-2023
Public Assessment Report Public Assessment Report Swedish 10-10-2019
Patient Information leaflet Patient Information leaflet Norwegian 28-03-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 28-03-2023
Patient Information leaflet Patient Information leaflet Icelandic 28-03-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 28-03-2023

Search alerts related to this product